logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Regenacy Pharmaceuticals, LLC

Calculating rank
USPTO Granted Patents = 16

% Expired Patents = 37.5


Forward Citations = 25

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Ralph Mazitschek (12 out of 63 patents)

silverMedal John Henry Van Duzer (12 out of 55 patents)

bronzeMedal Matthew B Jarpe (4 out of 5 patents)

4.  Annemieke Kavelaars (2 out of 3 patents)

5.  Cobi J Heijnen (2 out of 3 patents)

6.  Karen Krukowski (2 out of 2 patents)

7.  Olga Golonzhka (2 out of 2 patents)

8.  Charles Blum (1 out of 1 patent)


16 patents:

1. 11858919 - HDAC1,2 inhibitors (2024-01-02),
2. 11702389 - Piperidine derivatives as HDAC1/2 inhibitors (2023-07-18),
3. 11542242 - Substituted piperazines as selective HDAC1,2 inhibitors (2023-01-03),
4. 11013740 - Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy (2021-05-25),
5. 10968180 - Piperidine derivatives as HDAC1/2 inhibitors (2021-04-06),
6. 10858323 - HDAC inhibitors for the treatment of diabetic peripheral neuropathy (2020-12-08),
7. 10774056 - Substituted piperazines as selective HDAC1,2 inhibitors (2020-09-15),
8. 10385031 - Substituted piperazines as selective HDAC1,2 inhibitors (2019-08-20),
9. 10358421 - Piperidine derivatives as HDAC1/2 inhibitors (2019-07-23),
10. 10272084 - Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy (2019-04-30),
11. 10239837 - Piperidine derivatives as HDAC1/2 inhibitors (2019-03-26),
12. 10125131 - Selective HDAC3 inhibitors (2018-11-13),
13. 10040769 - HDAC inhibitors for the treatment of diabetic peripheral neuropathy (2018-08-07),
14. 9957259 - Selective HDAC1 and HDAC2 inhibitors (2018-05-01),
15. 9790180 - Piperidine derivatives as HDAC1/2 inhibitors (2017-10-17),
Company Overview
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Waltham, MA, focused on developing innovative therapies for patients with serious diseases. The company specializes in advancing treatments that target unmet medical needs, particularly in the areas of neurology and metabolic disorders. By leveraging cutting-edge research and technology, Regenacy aims to improve patient outcomes and enhance the quality of life for individuals affected by these conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Regenacy Pharmaceuticals, LLC USPTO Patent Assignee Logo
16 Patents

#91 in Waltham, MA

#1,204 in Massachusetts

#19,954 in US

#37,914 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Regenacy Pharmaceuticals, LLC

Forward Citations = 25

8 inventors:

goldMedal Ralph Mazitschek (12 out of 63 patents)

silverMedal John Henry Van Duzer (12 out of 55 patents)

bronzeMedal Matthew B Jarpe (4 out of 5 patents)

4.  Annemieke Kavelaars (2 out of 3 patents)

5.  Cobi J Heijnen (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Regenacy Pharmaceuticals, LLC. Retrieved from https://idiyas.com/company/regenacy-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…